MinuteClinic highlights access and outcomes in clinically supervised weight-loss program

Rhea-AI Summary

MinuteClinic, part of CVS (NYSE: CVS), is emphasizing its clinically supervised weight-loss program, available seven days a week in 49 states and DC via in-person and virtual care.

Outcomes as of 2026 show 85% of patients lost weight within three months, about two-thirds lost over 5% of body weight after five or more months, and 95% had a first visit within one week. Board-certified clinicians provide personalized plans, may prescribe FDA-approved medications including GLP-1s when appropriate, and integrate chronic disease management through MinuteClinic Primary Care, now at more than 60% of locations.

Positive

• Weight-loss program available in 49 states and DC with virtual and in-person access
• 85% of patients lost weight within their first three months in the program
• About two-thirds of patients lost more than 5% body weight after ≥5 months
• 95% of patients received their first visit within one week of scheduling
• MinuteClinic Primary Care now offered at more than 60% of MinuteClinic locations

Negative

• MinuteClinic does not prescribe GLP-1 medications in Massachusetts or Missouri
• Insurance coverage for GLP-1 therapies varies and patients may face differing out-of-pocket costs

News Market Reaction – CVS

+3.11%

+3.11% Session close to close

In the May 13 session, CVS gained 3.11%, reflecting a moderate positive market reaction.

Data tracked by StockTitan Argus on the day of publication.

Market Context

This announcement highlights MinuteClinic’s clinically supervised weight-loss program, with 85% of p...

Analysis

This announcement highlights MinuteClinic’s clinically supervised weight-loss program, with 85% of patients losing weight in three months and 95% seen within a week, addressing gaps in metabolic care access. It reinforces CVS’s strategy of using community clinics and virtual care to manage obesity and related conditions. Investors may watch how these services scale, payer coverage of GLP‑1 therapies, and links to chronic disease metrics and overall health care spending over time.

Key Figures

Early weight loss: 85% of patients Clinically meaningful loss: 5% weight reduction Access speed: 95% of patients +5 more

8 metrics

Early weight loss 85% of patients Lost weight within first three months of MinuteClinic program

Clinically meaningful loss 5% weight reduction Achieved by about two-thirds of patients within five or more months

Access speed 95% of patients Seen for first visit within one week of scheduling

Health spending $4.9 trillion Annual U.S. health care spending tied largely to chronic and mental health

Chronic share of spend Nearly 90% Portion of $4.9T U.S. health spending due to chronic and mental conditions

Obesity costs $173 billion Annual U.S. medical costs attributed to obesity

Primary care wait More than 20 days Average primary care appointment wait times in some markets

Overweight/obesity prevalence About 74% of adults U.S. adults meeting criteria for overweight or obesity

Historical Context

5 past events · Latest: May 06 (Positive)

Pattern 5 events

Date	Event	Sentiment	24h Move	Catalyst
May 06	Q1 2026 earnings	Positive	+7.7%	Strong Q1 results, revenue growth and higher EPS with raised full-year guidance.
May 05	Formulary changes	Positive	-1.6%	Biosimilar adoption via formulary updates aimed at improving affordability and access.
Apr 24	Prior auth progress	Positive	-1.2%	Simplified prior authorization processes and higher real-time approval rates at Aetna.
Apr 08	Provider survey	Positive	+0.7%	Survey showed provider optimism and targets for more real-time prior authorizations.
Apr 06	Earnings call notice	Neutral	-0.3%	Announcement of schedule and access details for Q1 2026 earnings call.

24h Move is the share-price change in the day after each event; other market factors may also have contributed.

Pattern Detected

Operational and strategic updates have produced mixed reactions, while earnings beats and guidance raises drew stronger positive responses.

Recent Company History

Over the last two months, CVS reported strong Q1 2026 results with raised full‑year guidance on May 6, which was followed by a 7.65% gain. Earlier news focused on formulary biosimilar shifts, prior authorization simplification, and provider sentiment, with modest and sometimes negative price moves despite operational improvements. Today’s MinuteClinic weight‑loss and primary care highlight continues the theme of expanding access, affordability, and care management capabilities within CVS’s integrated health platform.

Key Terms

glp-1 therapies, fda-approved

2 terms

glp-1 therapies medical

"providers may prescribe FDA-approved weight-loss medications, including GLP-1 therapies, alongside"

Drugs that mimic or boost the gut hormone GLP‑1, which helps control blood sugar and appetite by telling the body to release more insulin and feel full sooner; they are used to treat type 2 diabetes and obesity. Investors watch these therapies because they can drive large prescription sales, change healthcare spending and market share among drugmakers, and face regulatory, patent and competitive risks that directly affect company value.

fda-approved regulatory

"providers may prescribe FDA-approved weight-loss medications, including GLP-1 therapies"

FDA-approved means a medical product, drug, device or treatment has passed the U.S. Food and Drug Administration’s review for safety and effectiveness for a specific use. Think of it like a formal safety and performance seal that allows the product to be marketed for that purpose in the U.S.; for investors, approval reduces regulatory uncertainty, enables sales and reimbursement pathways, and can materially affect a company’s revenue prospects and valuation.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

In-person and virtual services support chronic disease prevention and long-term metabolic health

WOONSOCKET, R.I., May 13, 2026 /PRNewswire/ -- As chronic conditions tied to metabolic health continue to rise across the United States, MinuteClinic®, the medical clinic inside select CVS Pharmacy® (NYSE: CVS) locations, is highlighting its clinically supervised weight-loss program to support earlier intervention and more accessible preventive care.

Available in 49 states and the District of Columbia, the MinuteClinic weight-loss program offers seven-day-a-week access, including evenings and weekends, with both in-person and virtual care. As of 2026, the program has demonstrated strong outcomes:

• 85% of patients lost weight within their first three months
• About two-thirds of patients lost more than 5% of their weight within five or more months of treatment
• 95% of patients were seen for their first visit within one week of scheduling²

Chronic and mental health conditions account for nearly 90% of the nation's $4.9 trillion in annual health care spending, underscoring the growing monetary impact to patients living with conditions such as obesity, diabetes and cardiovascular disease. Obesity alone contributes nearly $173 billion in annual medical costs, while more than two in five U.S. adults have prediabetes — most of whom are unaware of their condition — highlighting a significant gap in early detection and intervention. This challenge is made even more complex by the fact that patients often face delays in accessing care, with wait times for a primary care appointment averaging more than 20 days in some markets.

The MinuteClinic weight-loss program delivers personalized, clinically supervised care designed to support chronic disease prevention and long-term health. Board-certified nurse practitioners and physician associates assess diet, physical activity, behavioral factors and underlying health conditions before recommending individualized treatment plans. When clinically appropriate, providers may prescribe FDA-approved weight-loss medications, including GLP-1 therapies, alongside ongoing nutrition counseling and lifestyle coaching¹.

With about 74% of U.S. adults meeting criteria for being overweight or obese, related metabolic risk factors such as insulin resistance, hypertension and elevated cholesterol often go undiagnosed or undertreated until later stages of disease. By offering convenient, community-based access to trusted care, MinuteClinic aims to support earlier clinical engagement and long-term management of these conditions.

"Improving metabolic health requires more than a single prescription; it requires ongoing clinical support, behavior change and access to care," said David Fairchild, MD, Chief Medical Officer, Retail Health, CVS Health. "By meeting patients where they are, we can help address risk factors earlier which ultimately supports long-term health outcomes and overall health care expenditures."

MinuteClinic can also serve as a primary care provider to eligible patients 18 and older. Launched in 2024 and continuing to expand across the U.S., MinuteClinic Primary Care enables providers to identify and manage related chronic conditions such as type 2 diabetes, high cholesterol and hypertension during the course of treatment. MinuteClinic Primary Care is now available at more than 60% of MinuteClinic locations in the U.S., helping to address multiple care needs in a single, accessible setting.

Services are covered by most insurance plans, with additional flexible payment options available.

To learn more, visit Minuteclinic.com.

¹ MinuteClinic does not prescribe GLP-1s in Massachusetts or Missouri. Insurance coverage for GLP-1s varies by insurer, and we encourage patients to contact their insurance company to confirm costs.
² Data as of 1/1/2026; engagement metrics and clinical outcomes reflect only that of patients who had more than two weight loss visits since 7/1/2024.

About CVS Health
CVS Health is a leading health solutions company simplifying health care one person, one family and one community at a time. As of March 31, 2026, the Company had approximately 9,000 retail pharmacy locations, more than 1,000 walk-in and primary care medical clinics and a leading pharmacy benefits manager with approximately 88 million plan members. The Company also serves an estimated more than 37 million people through a broad range of health insurance products and related services. The Company's integrated model uses personalized, technology driven services to connect people to simply better health, increasing access to quality care, delivering better outcomes, and lowering overall costs.

Media Contact
Shannon Dillon, CVS Health
Shannon.Dillon@CVSHealth.com
346.291.713

View original content to download multimedia:https://www.prnewswire.com/news-releases/minuteclinic-highlights-access-and-outcomes-in-clinically-supervised-weight-loss-program-302770446.html

SOURCE CVS Health

FAQ

What is the CVS (NYSE: CVS) MinuteClinic clinically supervised weight-loss program?

The MinuteClinic weight-loss program is a clinically supervised service offering personalized plans, lifestyle coaching, and when appropriate, FDA-approved medications. According to CVS, it supports chronic disease prevention and long-term metabolic health through board-certified clinicians in convenient community-based settings with flexible access.

What outcomes has the CVS MinuteClinic weight-loss program shown as of 2026?

According to CVS, 85% of MinuteClinic weight-loss patients lost weight within their first three months. About two-thirds lost more than 5% of body weight after five or more months, and 95% were seen for their first visit within one week of scheduling.

Where is the CVS MinuteClinic weight-loss program available and how can patients access it?

According to CVS, the MinuteClinic weight-loss program is available in 49 states and the District of Columbia. Patients can access care seven days a week, including evenings and weekends, through in-person clinic visits and virtual care options for greater scheduling flexibility.

Does the CVS MinuteClinic weight-loss program use GLP-1 medications?

When clinically appropriate, MinuteClinic providers may prescribe FDA-approved weight-loss medications, including GLP-1 therapies. According to CVS, GLP-1s are not prescribed in Massachusetts or Missouri, and insurance coverage for these drugs varies by insurer, so patients should confirm potential costs.

How does MinuteClinic Primary Care from CVS relate to the weight-loss program?

MinuteClinic Primary Care can manage chronic conditions identified during weight-loss treatment, such as type 2 diabetes and hypertension. According to CVS, this service, launched in 2024, is now available at more than 60% of MinuteClinic locations, allowing multiple care needs to be addressed together.

Are CVS MinuteClinic weight-loss services covered by insurance?

According to CVS, MinuteClinic services are covered by most insurance plans, with flexible payment options for patients. Coverage for specific components, such as GLP-1 weight-loss medications, varies by insurer, so individuals are encouraged to contact their insurance company to verify benefits and out-of-pocket costs.